Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk CEO to step down after eight years at the helm
09:35am, Friday, 16'th May 2025
Novo Nordisk (NYSE:NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years leading the Danish pharmaceutical giant, known for its blockbuster obesity and diabetes drugs Wegovy and Ozemp
Novo Nordisk CEO to step down amid pressure from obesity drug competition
09:25am, Friday, 16'th May 2025
Novo Nordisk (NYSE:NVO) has announced that chief executive Lars Fruergaard Jørgensen will step down after eight years in the role, as the company contends with growing pressure in the obesity treatme
Talks to replace Novo Nordisk CEO lasted several weeks, board chair says
09:17am, Friday, 16'th May 2025
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Re
Instant View: Wegovy-maker Novo Nordisk ousts CEO as competition in obesity drug market heats up
08:21am, Friday, 16'th May 2025
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk CEO to step down as competition weighs on Wegovy maker's share price
07:59am, Friday, 16'th May 2025
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news from Novo Nordisk.
Ozempic maker Novo Nordisk boots CEO over stock-price fall
07:37am, Friday, 16'th May 2025
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Frid
Novo Nordisk CEO to Step Down Amid Market Challenges
07:25am, Friday, 16'th May 2025
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
07:19am, Friday, 16'th May 2025
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørge
Novo Nordisk's CEO to step down as competition weighs on Wegovy maker's share price
07:12am, Friday, 16'th May 2025
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."
Novo Nordisk CEO to step down
07:07am, Friday, 16'th May 2025
Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down.
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
04:47am, Friday, 16'th May 2025
Bad news keeps coming for Novo Nordisk (NVO 2.58%). The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer.
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
11:00am, Thursday, 15'th May 2025
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
10:05am, Thursday, 15'th May 2025
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
09:50am, Thursday, 15'th May 2025
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Is It Time to Buy the Dip in Novo Nordisk Stock?
07:46am, Thursday, 15'th May 2025
Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S NYSE: NVO stock is still down nearly 50% in 2025. However, the stock is now trading near its 52-week low and is a discount t
